Adjuvant osimertinib showed an overwhelmingly positive effect on DFS benefit and reducing CNS metastases risk, further supporting osimertinib as a better adjuvant therapy and a new therapy standard for patients with EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.